What Has Been the Progress and Growth of the Anthracycline Market in Recent Years?
The anthracycline market has seen considerable growth due to a variety of factors.
• There has been a robust expansion in the anthracycline market in recent times. It is predicted to escalate from a worth of $1.52 billion in 2024 to approximately $1.62 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%.
The growth experienced in the previous period is credited to the increasing cases of cancer, the surging need for customized cancer therapies, heightened public awareness about the advantages of anthracyclines, and investments in the anthracycline sector.
How Does the Forecast Look for the Anthracycline Market?
The anthracycline market is expected to maintain its strong growth trajectory in upcoming years.
• The market of anthracycline is projected to witness steady growth in the upcoming years, reaching a value of $2.13 billion in 2029, with a compound annual growth rate (CAGR) of 7.1%.
This surge during the forecasted period can be linked to increasing awareness concerning cancer therapies, expansion in research and development dedicated to cancer treatment, amplified demand for efficient and easy-to-use cancer treatments, a rise in cancer screening programs, and governmental initiatives. The key trends expected during this forecast period are progression in anthracycline formulations, combined treatment methodologies, strategies for heart protection, as well as the creation of anthracyclines biosimilars.
What Are The Leading Drivers Of Growth In The Anthracycline Market?
The escalated frequency of cancer cases is projected to catalyze the growth of the anthracycline market. Various types of cancers, which can develop in almost any organ or tissue, occur when abnormal cells grow uncontrollably, breach their usual borders and either spread to other parts of the body or invade adjacent body parts. Anthracycline, a category of chemotherapy drugs, is crucial in the treatment of cancer since it hinders cell division by destabilizing the DNA structure and terminating its function. For instance, the American Cancer Society Inc., in 2023, predicts an expected 1.9 million new cancer diagnoses in the US, a rise from the 1.8 million new cases reported in 2020. In addition, an estimated 609,820 cancer-related deaths are forecasted in 2023, slightly above the projected 606,520 in 2020. Consequently, the escalating instances of cancer are fostering the growth of the anthracycline market. The propensity for growth in the anthracycline market is underpinned by the prominent demand for personalized medicine in the imminent future. Personalized, or precision medicines, refer to therapeutic treatments specially designed for individual patients, taking into account their particular genetic, molecular, and disease traits. This approach benefits from the precise usage of anthracycline chemotherapy drugs in conjunction with targeted treatments, culminating in more potent and less damaging therapy strategies. For instance, according to a report by the US-based health news firm, STAT, in October 2022, more than 75,000 genetic testing products and 300 personalized medicines were available. Moreover, in 2023, the Personalized Medicine Coalition suggested that the FDA had approved personalized medicines for 34% of new drugs in 2022, and a minimum of 25% of new drugs had received approval over the previous eight years. Thus, the mounting demand for personalized medicine is expected to stimulate the growth of the anthracycline market.
How Are The Segments Defined Within The Global Anthracycline Market?
The anthracycline market covered in this report is segmented –
1) By Drugs: Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin
2) By Dosage: Powder, Capsule, Solution, Injection, Suspension, Other Dosages
3) By Application: Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Bladder Cancer, Breast Cancer, Other Metastatic Cancers
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Daunorubicin: Daunorubicin Hydrochloride, Liposomal Daunorubicin
2) By Doxorubicin: Doxorubicin Hydrochloride, Liposomal Doxorubicin
3) By Epirubicin: Epirubicin Hydrochloride
4) By Idarubicin: Idarubicin Hydrochloride
5) By Mitoxantrone: Mitoxantrone Hydrochloride
6) By Valrubicin: Valrubicin Hydrochloride
Pre-Book The Anthracycline Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Anthracycline Industry?
Leading firms in the anthracycline market are striving to create groundbreaking products, such as formulations with no cardiotoxic effects. These are treatments or medications specifically created to lower or eradicate heart damage, especially those adverse effects typically linked to certain chemotherapy drugs, including anthracyclines, which could result in heart failure or additional heart-related problems. For instance, the Netherlands-based European Medicines Agency initiated Orphan Drug Designation for Annamycin, a new breed of anthracyclines meant for treating acute myeloid leukemia (AML), in April 2024. The designation of this drug provides substantial encouragements for the creation of treatments for uncommon diseases, giving a seven-year market exclusivity after approval. This prevents other manufacturers from distributing the identical drug for the same purpose. Moreover, companies receive tax reliefs accounting for up to 50% of clinical testing costs, waivers for application charges, and FDA's regulatory support. This helps in decreasing the financial responsibilities tied with developing medicines for smaller patient groups.
Who Are the Key Players In The Anthracycline Market?
Major companies operating in the anthracycline market are:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• Fresenius SE & Co. KGaA
• Merck & Co. Inc.
• Gilead Sciences Inc.
• Zydus Lifesciences Limited
• Viatris Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Jazz Pharmaceuticals Inc.
• Gland Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Hikma Pharmaceuticals PLC
• Endo Pharmaceuticals Inc.
• Amneal Pharmaceuticals Inc.
• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Accord Healthcare Limited
• Athenex Inc.
• Miracalus Pharma Pvt. Ltd.
• Transo-Pharm Usa LLC
• BluePoint Laboratories
• Areva Pharmaceuticals Inc.
• GeneraMedix Inc.
• Salius Pharma Pvt. Ltd.
What Is The Most Dominant Region In The Anthracycline Market?
Asia-Pacific was the largest region in the anthracycline market in 2024. The regions covered in anthracycline market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
